ARTICLE
15 February 2022

Australia Plans To Reopen To All Fully Vaccinated Visa Holders, Including Visitors

MB
Mayer Brown

Contributor

Mayer Brown is a distinctively global law firm, uniquely positioned to advise the world’s leading companies and financial institutions on their most complex deals and disputes. We have deep experience in high-stakes litigation and complex transactions across industry sectors, including our signature strength, the global financial services industry.
Effective February 21, 2022, the Australian government will reopen the country's borders to all fully vaccinated visa holders.
Australia Immigration

Effective February 21, 2022, the Australian government will reopen the country's borders to all fully vaccinated visa holders. The government's  announcement means that, for the first time in nearly two years, fully vaccinated tourists, business travelers, and others will be allowed to enter Australia without first receiving a travel exemption. The easing of entry restrictions also comes as Australia is experiencing a 23% decline in COVID-related hospitalizations as the omicron wave begins to fall.

Reopening to All Fully Vaccinated Visa Holders

Australia's decision to begin reopening the country to fully vaccinated tourists, business travelers, and others is a major milestone in the country's recovery from the COVID-19 pandemic. The move follows the government's  decision in December 2021 to allow exemption-free travel for fully vaccinated visa holders in specific subclasses, including the 482 – Temporary Skills Shortage visa and the 400 – Temporary Work (Short Stay Specialist) visa, among others.  The government's most recent announcement expands exemption-free travel eligibility to all fully vaccinated visa holders.

Visa holders who are not fully vaccinated will still require a valid travel exemption to enter Australia, and will be subject to state and territory quarantine requirements.

Recognized Vaccines and Proof of Vaccination Status

For travel purposes, the Australian government will consider an individual to be “fully vaccinated” if they have completed a course of a vaccine approved or recognized by the Therapeutic Goods Administration (TGA), including mixed doses. The current vaccines and dosages accepted for purposes of travel are:

  • One dose of the Johnson & Johnson (Janssen) vaccine; or
  • Two doses, at least 14 days apart, of the Pfizer-BioNTech, Moderna, AstraZeneca, Sinovac, Bharat Biotech, Sinopharm, Sputnik V, or Novavax vaccines.

At least seven days must have passed since the final dose of vaccine in a course of immunization for the traveler to be considered fully vaccinated. Travelers must present a print or digital copy of an  International COVID-19 Vaccination Certificate (ICVC) as proof of immunization.

Visit us at mayerbrown.com

Mayer Brown is a global legal services provider comprising legal practices that are separate entities (the "Mayer Brown Practices"). The Mayer Brown Practices are: Mayer Brown LLP and Mayer Brown Europe – Brussels LLP, both limited liability partnerships established in Illinois USA; Mayer Brown International LLP, a limited liability partnership incorporated in England and Wales (authorized and regulated by the Solicitors Regulation Authority and registered in England and Wales number OC 303359); Mayer Brown, a SELAS established in France; Mayer Brown JSM, a Hong Kong partnership and its associated entities in Asia; and Tauil & Chequer Advogados, a Brazilian law partnership with which Mayer Brown is associated. "Mayer Brown" and the Mayer Brown logo are the trademarks of the Mayer Brown Practices in their respective jurisdictions.

© Copyright 2020. The Mayer Brown Practices. All rights reserved.

This Mayer Brown article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More